Exiting the European Union

Proposes to take motions for the Human Fertilisation and Embryology (Amendment) (EU Exit), Human Tissue (Quality and Safety for Human Application) (Amendment) (EU Exit), and Quality and Safety of Organs Intended for Transplantation (Amendment) (EU Exit) Regulations 2020, all laid before this House on 8 October.

Emphasises the technical but life-saving importance of the regulations. He raises concerns about implementation timing for Northern Ireland, divergence plans in Great Britain, and the Medicines and Medical Devices Bill's interaction with these regulations. Also asks about blood products delay assurance and organ transplant assurance from Great Britain to Northern Ireland.

Expresses gratitude for the opportunity to raise questions on organ transplants. Discusses personal experience with a nephew who received kidney transplant and highlights importance of continuing transplants during pandemic. Raises concern over use of aborted babies' tissues in regulations.

Argued that the UK Government is committed to implementing the Northern Ireland protocol and related regulations in good time. Mentioned ongoing negotiations with the European Union without prejudging outcomes. Reiterated the government's intent to remain world-leading on issues covered by these regulations. Stressed the importance of working closely with industry and publishing guidance for a seamless transition. Offered reassurance regarding the movement of blood, blood components, and organs between UK nations and EU countries.